Skip to main content
. 2016 Aug 9;16:618. doi: 10.1186/s12885-016-2662-x

Table 1.

Clinico-pathological characteristics at primary diagnosis and -652 6N InsDel genotype distribution

All CASP8 -652 6N InsDel genotype P-value
InsIns InsDel DelDel
n (%) 200 42 (21.0) 101 (50.5) 57 (28.5)
Age at diagnosis (years ± SD) 56.46 ± 12.1 55.00 ± 10.4 57.19 ± 12.4 56.26 ± 12.6 0.676
Tumor type
 Ductal 136 (68.0) 28 (20.6) 68 (50.0) 40 (29.4) 0.243
 Lobular 43 (21.5) 12 (27.9) 23 (53.5) 8 (18.6)
 Others 21 (10.5) 2 (9.5) 10 (47.6) 9 (42.9)
Tumor size (mm ± SD) 24.20 ± 16.8 23.51 ± 19.2 25.11 ± 17.1 23.07 ± 14.5 0.837
Tumor stage
 pT1 107 (53.5) 24 (22.4) 53 (49.5) 30 (28.1) 0.540
 pT2 71 (35.3) 11 (15.5) 39 (54.9) 21 (29.6)
 pT3+4 22 (11.0) 7 (31.8) 9 (40.9) 6 (27.3)
Lymph node status
 pN0 115 (57.5) 24 (20.9) 61 (53.0) 30 (26.1) 0.592
 pN+ 85 (42.5) 18 (21.2) 40 (47.1) 27 (31.8)
UICC stage
 I 76 (38.0) 17 (22.4) 37 (48.7) 22 (28.9) 0.442
 II 78 (39.0) 13 (16.7) 46 (59.0) 19 (24.4)
 III + IV 46 (23.0) 12 (26.0) 18 (39.1) 11 (23.9)
Grade
 1 71 (37.4) 16 (22.5) 35 (49.3) 20 (28.2) 0.379
 2 68 (35.8) 10 (14.7) 40 (58.8) 18 (26.5)
 3 51 (26.8) 13 (25.5) 21 (41.2) 17 (33.3)
Estrogen receptor status
 negative 53 (32.5) 12 (7.4) 29 (17.8) 12 (7.4)
 positive 110 (67.5) 25 (15.3) 50 (30.7) 35 (21.5) 0.432
Her2 status
 negative 138 (83.6) 30 (18.1) 68 (41.2) 40 (24.2) 0.835
 positive 27 (16.4) 5 (3.0) 15 (9.1) 7 (4.2)
Treatment
 Surgical treatment
  breast conserving 50 (25.0) 10 (20.0) 23 (46.0) 17 (34.0) 0.604
  ablative 150 (75.0) 32 (21.3) 78 (52.0) 40 (26.7)
 Adjuvant therapy
  no adjuvant therapy 112 (56.0) 22 (19.6) 62 (57.1) 28 (25.0) 0.285
  Tam and/or CMF 88 (44.0) 20 (22.7) 39 (44.3) 29 (33.0)

Tam Tamoxifen, CMF cyclophosphamide, methotrexate and 5 fluorouracil. Data are numbers with percentages given in brackets. Categorical variables were analyzed by χ2 statistics. P values were calculated using ANOVA for continuous variables